Navigation Links
Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai

WORCESTER, Mass. and TORONTO, Dec. 7, 2011 /PRNewswire/ -- Generex Biotechnology Corporation ( (OTCBB: GNBT) announced today that a group of physicians led by Professor Paolo Pozzilli at the University Campus Bio-Medico in Rome, Italy, will provide an update on results of using Generex Oral-lyn™  as it pertains to prediabetes at  the forthcoming International Diabetes Federation (IDF) Congress, to be held in Dubai, December 3rd-8th, 2011.


The paper is entitled "Buccal Spray Insulin for The Treatment of Impaired Glucose Tolerance" and is presented by Dr. Y.M. Khazrai of Dr. Pozzilli's research team.

The study results confirm and significantly extend previous beneficial results showing that subjects with impaired glucose tolerance (IGT) treated with the Generex Oral-lyn™ buccal insulin spray achieved a significant reduction of 0.3% in HbA1c compared to the control group (∆ HbA1c 0'- 6 month  -0.3% vs +0.09%, p= 0.002).   Although the decrease in body weight in Generex Oral-lyn™ treated subjects did not reach significance in this short term study, there were no reports of hypoglycemia or other adverse events observed during the study period compared to control subjects.   These preliminary results suggest that the addition of Generex Oral-lyn™ can be an effective treatment compared to diet and physical exercise alone in subjects with IGT in reducing HbA1c and doing so without adverse effects.

"These results suggest Generex Oral-lyn™ will be an important therapy tool for adults with prediabetes conditions of IGT and elevated blood-sugar levels," said Dr. James H. Anderson, Jr., MD, FFPM, FACE, Generex's Senior Scientific Advisor.  "The opportunity to successfully expand Generex Oral-lyn™'s use beyond Type 1 diabetes and Type 2 diabetes offers a validated therapy to not only treat and improve the quality of life of those who will eventually be diagnosed with diabetes, but also provides a solution for the diabetes medical community to potentially reduce or prevent the progression of the complications that may arise from having diabetes."

Prediabetes is a condition in which individuals have blood glucose or A1c levels higher than normal but not high enough to be classified as diabetes.  People with prediabetes have an increased risk of developing type 2 diabetes, heart disease, and stroke.  According to the Center for Disease Control and Prevention, it is estimated that in 2010, 79 million people 20 years of age or older have pre-diabetes, and approximately 50% of Americans aged 65 and older have pre-diabetes.

About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at or the Antigen Express website at

Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
2. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
3. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
4. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
5. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
6. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
7. CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team
8. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
9. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
10. Patent Technologies Keep CGMT in a Leading Position in the Industry
11. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
Post Your Comments:
(Date:11/30/2015)... 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the ... C.W. Wong to its Board of Directors to replace ... with a wealth of experience as co-founder of Resverlogix, with ... --> --> Dr. Wong remarked, ... of directors. Zenith,s long standing expertise in epigenetics and the ...
(Date:11/30/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... presenting at the 8 th Annual LD Micro ... PT. Dr. John N. Bonfiglio a TapImmune ... presentation and will join TapImmune management in meeting with ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
Breaking Biology Technology:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
Breaking Biology News(10 mins):